BIOMARIN PHARMACEUTICAL INC (BMRN) Stock Fundamental Analysis
USA - NASDAQ:BMRN - US09061G1013 - Common Stock
52.3 USD
-1.86 (-3.43%)
We assign a fundamental rating of 6 out of 10 to BMRN. BMRN was compared to 533 industry peers in the Biotechnology industry. BMRN scores excellent points on both the profitability and health parts. This is a solid base for a good stock. BMRN scores decently on growth, while it is valued quite cheap. This could make an interesting combination. With these ratings, BMRN could be worth investigating further for value and quality investing!.
1. Profitability
1.1 Basic Checks
BMRN had positive earnings in the past year.
BMRN had a positive operating cash flow in the past year.
Of the past 5 years BMRN 4 years were profitable.
BMRN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of 6.83%, BMRN belongs to the best of the industry, outperforming 92.87% of the companies in the same industry.
BMRN has a better Return On Equity (8.59%) than 92.50% of its industry peers.
BMRN has a Return On Invested Capital of 7.69%. This is amongst the best in the industry. BMRN outperforms 93.81% of its industry peers.
BMRN had an Average Return On Invested Capital over the past 3 years of 3.73%. This is significantly below the industry average of 19.19%.
The 3 year average ROIC (3.73%) for BMRN is below the current ROIC(7.69%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.83% | ||
| ROE | 8.59% | ||
| ROIC | 7.69% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 16.82%, BMRN belongs to the best of the industry, outperforming 93.62% of the companies in the same industry.
The Operating Margin of BMRN (20.21%) is better than 94.37% of its industry peers.
Looking at the Gross Margin, with a value of 81.32%, BMRN belongs to the top of the industry, outperforming 85.18% of the companies in the same industry.
BMRN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.21% | ||
| PM (TTM) | 16.82% | ||
| GM | 81.32% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BMRN is destroying value.
Compared to 1 year ago, BMRN has more shares outstanding
Compared to 5 years ago, BMRN has more shares outstanding
The debt/assets ratio for BMRN has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 5.20 indicates that BMRN is not in any danger for bankruptcy at the moment.
BMRN has a better Altman-Z score (5.20) than 75.05% of its industry peers.
BMRN has a debt to FCF ratio of 0.72. This is a very positive value and a sign of high solvency as it would only need 0.72 years to pay back of all of its debts.
BMRN has a better Debt to FCF ratio (0.72) than 94.37% of its industry peers.
A Debt/Equity ratio of 0.10 indicates that BMRN is not too dependend on debt financing.
The Debt to Equity ratio of BMRN (0.10) is worse than 63.23% of its industry peers.
Even though the debt/equity ratio score it not favorable for BMRN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.72 | ||
| Altman-Z | 5.2 |
ROIC/WACC0.93
WACC8.3%
2.3 Liquidity
BMRN has a Current Ratio of 4.83. This indicates that BMRN is financially healthy and has no problem in meeting its short term obligations.
BMRN has a Current ratio (4.83) which is in line with its industry peers.
BMRN has a Quick Ratio of 3.10. This indicates that BMRN is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of BMRN (3.10) is worse than 60.41% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.83 | ||
| Quick Ratio | 3.1 |
3. Growth
3.1 Past
BMRN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.00%, which is quite impressive.
Looking at the last year, BMRN shows a quite strong growth in Revenue. The Revenue has grown by 12.39% in the last year.
Measured over the past years, BMRN shows a quite strong growth in Revenue. The Revenue has been growing by 10.86% on average per year.
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%
3.2 Future
BMRN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.59% yearly.
Based on estimates for the next years, BMRN will show a small growth in Revenue. The Revenue will grow by 7.34% on average per year.
EPS Next Y37.42%
EPS Next 2Y42.81%
EPS Next 3Y33.39%
EPS Next 5Y27.59%
Revenue Next Year12.45%
Revenue Next 2Y9.95%
Revenue Next 3Y9.2%
Revenue Next 5Y7.34%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 19.66 indicates a rather expensive valuation of BMRN.
BMRN's Price/Earnings ratio is rather cheap when compared to the industry. BMRN is cheaper than 93.81% of the companies in the same industry.
When comparing the Price/Earnings ratio of BMRN to the average of the S&P500 Index (25.46), we can say BMRN is valued slightly cheaper.
The Price/Forward Earnings ratio is 11.60, which indicates a very decent valuation of BMRN.
Based on the Price/Forward Earnings ratio, BMRN is valued cheaply inside the industry as 97.00% of the companies are valued more expensively.
BMRN's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 35.39.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.66 | ||
| Fwd PE | 11.6 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BMRN indicates a rather cheap valuation: BMRN is cheaper than 95.12% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BMRN indicates a rather cheap valuation: BMRN is cheaper than 97.37% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.16 | ||
| EV/EBITDA | 13.12 |
4.3 Compensation for Growth
BMRN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BMRN has a very decent profitability rating, which may justify a higher PE ratio.
BMRN's earnings are expected to grow with 33.39% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.53
PEG (5Y)N/A
EPS Next 2Y42.81%
EPS Next 3Y33.39%
5. Dividend
5.1 Amount
BMRN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:BMRN (11/19/2025, 2:58:08 PM)
52.3
-1.86 (-3.43%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners98.83%
Inst Owner Change-1.19%
Ins Owners0.65%
Ins Owner Change2.28%
Market Cap10.04B
Revenue(TTM)3.09B
Net Income(TTM)520.42M
Analysts83.53
Price Target95.71 (83%)
Short Float %5.18%
Short Ratio4.01
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-48.87%
Min EPS beat(2)-142.18%
Max EPS beat(2)44.44%
EPS beat(4)3
Avg EPS beat(4)-11.96%
Min EPS beat(4)-142.18%
Max EPS beat(4)44.44%
EPS beat(8)6
Avg EPS beat(8)2.48%
EPS beat(12)9
Avg EPS beat(12)14.79%
EPS beat(16)12
Avg EPS beat(16)-9.32%
Revenue beat(2)1
Avg Revenue beat(2)1.98%
Min Revenue beat(2)-2.53%
Max Revenue beat(2)6.48%
Revenue beat(4)2
Avg Revenue beat(4)1.32%
Min Revenue beat(4)-2.53%
Max Revenue beat(4)6.48%
Revenue beat(8)4
Avg Revenue beat(8)1.53%
Revenue beat(12)5
Avg Revenue beat(12)0.37%
Revenue beat(16)7
Avg Revenue beat(16)0.03%
PT rev (1m)-1.71%
PT rev (3m)-2.04%
EPS NQ rev (1m)11.36%
EPS NQ rev (3m)12.48%
EPS NY rev (1m)-13.82%
EPS NY rev (3m)-13.73%
Revenue NQ rev (1m)0.51%
Revenue NQ rev (3m)0.73%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)0.87%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.66 | ||
| Fwd PE | 11.6 | ||
| P/S | 3.25 | ||
| P/FCF | 12.16 | ||
| P/OCF | 10.99 | ||
| P/B | 1.66 | ||
| P/tB | 1.78 | ||
| EV/EBITDA | 13.12 |
EPS(TTM)2.66
EY5.09%
EPS(NY)4.51
Fwd EY8.62%
FCF(TTM)4.3
FCFY8.22%
OCF(TTM)4.76
OCFY9.1%
SpS16.11
BVpS31.54
TBVpS29.31
PEG (NY)0.53
PEG (5Y)N/A
Graham Number43.45
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.83% | ||
| ROE | 8.59% | ||
| ROCE | 9.17% | ||
| ROIC | 7.69% | ||
| ROICexc | 9.82% | ||
| ROICexgc | 10.68% | ||
| OM | 20.21% | ||
| PM (TTM) | 16.82% | ||
| GM | 81.32% | ||
| FCFM | 26.69% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
ROICexc(3y)4.34%
ROICexc(5y)N/A
ROICexgc(3y)4.77%
ROICexgc(5y)N/A
ROCE(3y)4.44%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
F-Score8
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.72 | ||
| Debt/EBITDA | 0.84 | ||
| Cap/Depr | 106.6% | ||
| Cap/Sales | 2.85% | ||
| Interest Coverage | 85.91 | ||
| Cash Conversion | 129.08% | ||
| Profit Quality | 158.68% | ||
| Current Ratio | 4.83 | ||
| Quick Ratio | 3.1 | ||
| Altman-Z | 5.2 |
F-Score8
WACC8.3%
ROIC/WACC0.93
Cap/Depr(3y)111.01%
Cap/Depr(5y)114.82%
Cap/Sales(3y)4.71%
Cap/Sales(5y)5.6%
Profit Quality(3y)57.85%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
EPS Next Y37.42%
EPS Next 2Y42.81%
EPS Next 3Y33.39%
EPS Next 5Y27.59%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%
Revenue Next Year12.45%
Revenue Next 2Y9.95%
Revenue Next 3Y9.2%
Revenue Next 5Y7.34%
EBIT growth 1Y52.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year97.49%
EBIT Next 3Y41.32%
EBIT Next 5Y23.21%
FCF growth 1Y2529.91%
FCF growth 3Y36.9%
FCF growth 5YN/A
OCF growth 1Y559.43%
OCF growth 3Y23.45%
OCF growth 5Y63.99%
BIOMARIN PHARMACEUTICAL INC / BMRN FAQ
Can you provide the ChartMill fundamental rating for BIOMARIN PHARMACEUTICAL INC?
ChartMill assigns a fundamental rating of 6 / 10 to BMRN.
Can you provide the valuation status for BIOMARIN PHARMACEUTICAL INC?
ChartMill assigns a valuation rating of 8 / 10 to BIOMARIN PHARMACEUTICAL INC (BMRN). This can be considered as Undervalued.
Can you provide the profitability details for BIOMARIN PHARMACEUTICAL INC?
BIOMARIN PHARMACEUTICAL INC (BMRN) has a profitability rating of 7 / 10.
What is the expected EPS growth for BIOMARIN PHARMACEUTICAL INC (BMRN) stock?
The Earnings per Share (EPS) of BIOMARIN PHARMACEUTICAL INC (BMRN) is expected to grow by 37.42% in the next year.